Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers.
The 80,000 square foot space is spread across three buildings with research labs attached to it, KBI spokesman Andrew Cohen told us.
Joe McMahon, KBI’s President and CEO, noted, “KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L.”
The site offers stainless steel bioreactors, Cohen added, noting that the company’s sites in North Carolina uses single use bioreactors.
“There’s still open capacity as we go through this transition,” Cohen said.
KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.
To date, KBI has helped to advance more than 220 molecules in 55 unique health indications for over 170 clients worldwide.